secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001837607-24-000092
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma Q3 2024: FDA aligned on biosimilar path for ABP-450, but capital constraints persist
--------------------------------------------------------------------------------

- Held Biosimilar Initial Advisory meeting with FDA in Q3; aligned on 351(k) pathway using BOTOX as reference.
- Primary comparative analytical studies planned for Q4 2024, subject to securing capital resources.
- BPD Type 2 meeting with FDA targeted in 2025 to discuss study outcomes.
- CEO cites capital resources as single biggest limitation; evaluating all options to fund regulatory strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000092/0001837607-24-000092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000092/aeon-20241113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-24-000092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer